• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

    13.54 -0.34 (-2.45%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Contineum Therapeutics, Inc. - Common stock

    < Previous 1 2 Next >
    Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗
    Via Chartmill
    News headline image
    Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
    From Contineum Therapeutics
    Via Business Wire
    News headline image
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
    Via Chartmill
    News headline image
    Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
    Via Benzinga
    News headline image
    This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at September Investor Conferences
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Contineum (CTNM) Q2 R&D Jumps 78% ↗
    Via The Motley Fool
    News headline image
    Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.